Recently added

Now showing items 1-5 of 11816

Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML

1999- Steegmann, Juan Luís; Odriozola, Jesús; Rodriguez Salvanés, Francisco; Giraldo, Pilar; García Laraña, José; [et al.]
Familial Myeloproliferative Syndrome

1994- Pérez Encinas, Manuel Mateo; Bello López, José Luis; Pérez Crespo, Susana; De Miguel, R.; Tome, S. [et al.]
Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma

1998- Pérez Encinas, Manuel Mateo; Villamayor Álvarez, Mercedes; Campos Pena, Alfredo; González Pérez, Marta Sonia; Bello López, José Luis [et al.]
A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses

2003- Penarrubia, M. J.; Odriozola, J.; González, C.; Massagué, I.; Miguel, A.; [et al.]
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

2016- Álvarez-Larrán, Alberto; Kerguelen, Ana; Hernández-Boluda, Juan Carlos; Pérez Encinas, Manuel Mateo; Ferrer-Marín, Francisca; [et al.]